Sector News

Which pharma execs win the popularity contest?

May 24, 2017
Life sciences

Sometimes adult life sends us through a disturbing time warp. It’s much too reminiscent of high school.

The cool kids’ cafeteria table (or parking lot, where I grew up) becomes the cool grown-up party at J.P. Morgan, for instance. Step into biopharma Twitter, where the snark level sometimes hits Mean Girls levels.

But today, it’s the “best all-around” votes senior year echoed in post-high school reality. Only instead of the most popular graduating senior, these votes chose the most congenial CEOs in biopharma.

The business-information analysts over at Owler sifted through various data streams, including its own CEO rating tool (smile, frown or in-between) to come up with a ranking of the best-liked pharma leaders. The top 10 is mostly packed with Big Pharma’s top dogs, with a couple of surprises in the mix.

Including No. 1, Sanjay Bhatia of Laborate Pharmaceuticals, a small, privately held drugmaker in Delhi, India. His approval rating with Owler’s tool? A stunning 99 out of 100. And it’s not because he has 100 employees who all voted with a smile. Laborate has an estimated 5,180 staffers and 1,980 followers on the Owler site.

Roche and its Genentech unit swept second and third, with Roche’s Severin Schwan in second place with a 92.9 approval rating. Bill Anderson at Genentech clocked an 87.7. Switzerland-based Roche bought the share of California-based Genentech it didn’t already own back in 2009, and the Genentech side of the business has delivered some of Roche’s biggest-selling drugs in the last few years.

AbbVie’s Richard Gonzalez comes in fourth with an 83.8 approval rating—he’s been at the helm at that company since it was spun off by Abbott Laboratories in 2013. He’s consistently among the highest-paid CEOs in the industry, and while popularity among staff isn’t among his compensation metrics, driving “employee engagement” is.

Rounding out the top five is Shire’s Flemming Ornskov, whose most recent claim to fame is the company’s buyout of Bioverativ, the hemophilia unit spun off by Baxter last year.

The rest of the top 10? Merck’s Ken Frazier; GlaxoSmithKline’s Emma Walmsley, who’s brand-new to the Glaxo CEO post; Johnson & Johnson’s Alex Gorsky; and Bayer’s relatively new chief, Werner Baumann. Steven H. Collis, CEO of the drug distributor AmerisourceBergen, came in seventh. All of their ratings fell in the 70s.

This is not, of course, a randomized, statistically weighted survey with a p-value of less than 0.05. For all we know, one or more of the CEOs in the top 10 has a master plan to boost online ratings—good reviews, up votes, etcetera. But a couple of facts to walk away with are these: As a group, biotech and pharma CEOs came in 13th, ratings-wise, when measured against other industries.

Pretty average for likability, an Owler spokeswoman said in a statement. Those ratings “suggest that CEOs leading at pharma and biotech companies, in terms of favorability, are in the middle of the pack relative to CEOs in other industries.”

By Tracy Staton

Source: Fierce Pharma

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach